How surprised are you that AGN’s DARPIn program is apparently a failure?
Well, AGN didn't specify what went wrong in DARPin's trial (did they?) and if they do another phase II with higher dose then the problem is probably that duration of action isn't long enough to compete with marketed anti-VEGF's. I am surprised, I was quite optimistic about this program.
Market Data 
Markets 
AI
